

.....

LIST OF FIGURES

Figure No.	Figure captions	Page Nos.
1.1	Pictorial diagram of testicular androgenesis	
1.2	Arrangement of different generation of germ cells at different stages of spermatogenic cycle at rat	
1.3	Testicular cross section at stage VII of seminiferous epithelial cell cycle shows different generation of germ cells (Fig. 2 X 1000)	
1.4	Generation of reactive oxygen species in human spermatozoa. NADPH: nicotinamide adenine dinucleotide phosphate, NADH: nicotinamide adenine dinucleotide, SOD: superoxide dismutase, Cu: copper, Fe: Iron.	
1.5	Apoptotic mitochondrial pathway (signalling pathway) for the activation of caspase cascade system	
1.6	Extrinsic pathway for maintaining programme cell death	
4.1.1	Activity of testicular $\Delta 5$, 3β -HSD and 17β -HSD after cyproterone acetate treatment	
4.1.2	Effect of cyproterone acetate on testicular cholesterol level in male albino rat	
4.1.3	Catalase activity in testis, sperm pellet and prostate in CPA treated albino rat	
4.1.4	Adverse effect of cyproterone acetate on superoxide dismutase activity in testis, sperm pellet and prostate in albino rat	
4.1.5	Toxicity assessment of CPA in general in male albino rat	
4.1.6	Negative deviation in the seminiferous tubular diameter after cyproterone acetate administration to the male albino rat	
4.2.1	Rectification in the sperm acrosomal status after lycopene administration at different doses in CPA treated infertile rat	
4.2.2	Effect of different doses of lycopene on androgenic key enzyme activities to the CPA treated rat with andrological abnormalities	
4.2.3	Corrective efficacy of different doses of lycopene on the testicular cholesterol level on CPA administered infertile rat	
4.2.4	Attenuation in the serum testosterone level after the treatment with lycopene at different doses to the CPA treated infertile rat	
4.2.5	Protective efficacy of lycopene at the doses of 0.75 mg, 1.5 mg, 3.0 mg and 4.5 mg in connection to the rectification in catalase activities in testis and sperm pellet to the CPA treated rat	
4.2.6	Dose dependent remedial effect of lycopene on the peroxidase activities in sperm pellet and testis in CPA treated infertile rat	
4.2.7	Protective efficacy of lycopene at the doses of 0.75 mg, 1.5 mg, 3.0 mg and 4.5 mg in connection to the rectification in catalase activity in testis and sperm pellet to the CPA treated rat	

4.2.8	Recovery in the serum protein profile after the treatment of lycopene at 0.75 mg, 1.5 mg , 3.0 mg and 4.5 mg doses to the CPA induced hypo-testicular activities in rat	
4.3.1	Corrective efficacy of lycopene on nuclear chromatin decondensation after treatment with 15 days, 30 days and 45 days on CPA induced hypo-testicular dysfunction in male infertile rat	
4.3.2	Rectification in the testicular $\Delta 5$, 3β -HSD activity after lycopene administration in different durations in CPA treated infertile rat	
4.3.3	Correction in the testicular 17β , 3β -HSD activity after lycopene administration in different durations in CPA treated infertile rat	
4.3.4	Rectification in the testicular cholesterol level by duration dependent lycopene treatment on CPA induced male infertile rat	
4.3.5	Ameliorative efficacy of lycopene on testosterone level at different duration depend treatment protocol on CPA induced male infertile rat.	
4.3.6	Duration dependent revival efficacy of lycopene on seminal vascular fructose level on CPA induced male infertile rat	
4.3.7	Duration dependent ameliorative efficacy of lycopene on testicular catalase activity on CPA induced male infertile rat	
4.3.8	Correction of testicular SOD activity by duration dependent treatment regimen with lycopene on CPA induced male infertile rat	
4.3.9	Rectification in the serum GOT and GPT activities after lycopene treatment in different duration dependent regimen in CPA induced male infertile rat	
4.4.1	Effect of 30 days treatment followed by cessation of lycopene treatment for 15, 30 or 45 days on testicular $\Delta 5$, 3β -HSD activity in CPA treated rat	
4.4.2	Activity of 17β -HSD in testicular tissue after the treatment with lycopene for 30 days followed by withdrawal of treatment for 15, 30 or 45 days	
4.4.3	Rectification in serum testosterone level after treatment with lycopene for 30 days followed by cessation of treatment for 15, 30 or 45 days in CPA treated albino rats	
4.4.4	Rectification in seminal vascular fructose level after treatment with lycopene for 30 days followed by cessation of treatment for 15, 30 or 45 days in CPA treated albino rats	
4.4.5	Testicular SOD activity after the treatment with lycopene for 30 days followed by withdrawal of treatment for 15, 30 or 45 days in CPA treated albino rats	
4.4.6	Activity of testicular GST after 30 days of lycopene treatment followed by cessation of treatment for 15, 30 or 45 days in CPA treated infertile albino rats	
4.4.7	Testicular catalase activity after oral administration of lycopene for 30 days followed by withdrawal of treatment for 15, 30 or 45	

	days in CPA treated infertile albino rats	
4.4.8	Effect of withdrawal of lycopene treatment for 15, 30 or 45 days on testicular peroxidase activity on CPA induced hypo-testicular dysfunction in male albino rat	
4.4.9	Effect of withdrawal of lycopene treatment for 15, 30 or 45 days on testicular antioxidant end products levels on CPA induced hypo-testicular dysfunction in male albino rat	
4.5.1	Correction in the gene expression by qRT-PCR of testicular $\Delta 5$, 3β-HSD after lycopene administration in CPA treated infertile rat.	
4.5.2	qRT-PCR study of testicular 17β-HSD gene expression after oral administration of lycopene in CPA pre-treated infertile rat	
4.5.3	Up-regulation in testicular catalase gene expression after lycopene treatment in CPA pre-treated infertile albino rats	
4.5.4	Correction in the testicular SOD gene expression after lycopene treatment in CPA pre-treated infertile albino rats	
4.5.5	qRT-PCR study of testicular peroxidase gene expression after lycopene treatment in CPA pre-treated infertile albino rats	
4.5.6	Rectification in the gene expression of testicular Bax after lycopene treatment in CPA pre-treated infertile albino rats	
4.5.7	Bcl-2 gene expression in testicular tissue after the correction in expression pattern by lycopene in albino male rats	
4.5.8	Rectification in the cytochrome-c gene expression in testicular tissue after oral administration of lycopene to the CPA induced infertile rat	
4.5.9	Corrective efficacy of lycopene on the gene expression pattern of testicular caspase 3, 8 and 9 in testicular tissue after oral administration of lycopene to the CPA-induced infertile rat	
4.5.10	Western blot analysis of testicular $\Delta 5$, 3β-HSD protein expression after lycopene administration in CPA treated infertile rat	
4.5.11	Ameliorative efficacy of lycopene on testicular 17β-HSD protein expression on CPA treated infertile male rat	
4.5.12	Rectification in the protein expression of testicular catalase after administration of lycopene in CPA pre-treated albino rats	
4.5.13	Rectification in the protein expression of testicular SOD after administration of lycopene in CPA pre-treated albino rats	
4.5.14	Western blot analysis of testicular Bax protein expression after lycopene administration in CPA pre-treated albino rat	
4.5.15	Attenuation of testicular Bcl-2 protein expression by lycopene in CPA treated infertile male rat.	
4.5.16	Correction of testicular Bcl-2 protein expression by lycopene in CPA pre-treated infertile male rat	
4.5.17	Flow cytometry analysis of viable sperm in A. Vehicle treated control, B. CPA treated rat, C. CPA+ lycopene treatment	
4.5.18	Effect of lycopene on sperm mitochondrial integrity in A. vehicle treated control, B. CPA treated group and C. CPA+ lycopene treated group	
4.5.19	Remedial effect of lycopene on sperm DNA breakage through	

	comet assay in A. vehicle treated control, B. CPA treated group and C. CPA+ lycopene treated group	
4.5.20	Immunohistochemical study of testicular tissue for the detection of apoptosis in A. vehicle treated control, B. CPA treated group and C. CPA+ lycopene treated group	
4.6.1	Direct effect of lycopene exposure on testicular $\Delta 5$, 3β-HSD, 17 β-HSD activities in CPA treated infertile male rats	
4.6.2	Remedial effect of lycopene after its direct exposure to the testis of CPA pre-treated infertile rats	
4.6.3	Rectification in the catalase activity after the direct exposure lycopene at the dose of 1.5 mg/ 0.5 ml tween-80 CPA pre-treated infertile rats	
4.6.4	Rectification in the catalase activity after the direct exposure lycopene at the dose of 1.5 mg/ 0.5 ml tween-80 CPA pre-treated infertile rats.	
4.6.5	<i>In vitro</i> study on effectiveness of lycopene on GST activity in testes of the animals treated with CPA	
4.6.6	Ameliorative effect of lycopene on acid phosphatase and alkaline phosphatase activities in testes after direct exposure of lycopene on the testes of CPA pre-treated infertile rats	
4.7.1	Serum GOT and GPT enzyme activities after administration of lycopene at the potent dose to the albino rats and its comparison to the vehicle treated control	
4.7.2	Activities of hepatic and renal ALP after the administration of lycopene at 1.5 mg/ 0.5 ml tween-80/ 100 g body weight to the experimental rat	
4.7.3	Effect of lycopene on renal and hepatic ACP activity in albino rats.	
4.7.4	Serum total protein, albumin and globulin levels after treatment with lycopene at the potent dose	
4.7.5	Effect of oral administration of lycopene on urea, BUN and creatinine levels in Wistar strain albino rats	
4.8.1	Diagrammatic presentation of the number of spermatozoa present in the vaginal swab of the female rat mated with the male rats of different groups	